Glaukosの空売り状況は、投資家がGlaukosの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Glaukos (NYSE:GKOS) 株価情報, 空売り情報

Glaukos

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos Corp

Glaukos Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million.
The eye-focused company reported an adjusted EPS loss of $(0.28), down from a loss of $(0.50), beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41727155/glaukos-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $(0.48)</a>.
The gross margin for the third quarter of 2024 was approximately 77%, compared to approximately 76% in the same period in 2023.
Non-GAAP gross margin for the third quarter of 2024 was approximately 82%, compared to approximately 83% in the same period in 2023.
Glaucoma products recorded net sales of $76.0 million, up 30% year-over-year. Corneal Health net sales reached $20.6 million, increased 5% year-over-year.
"Our record third-quarter results reflect successful global execution of our key strategic plans and continued strong momentum in our business," said Thomas Burns, chairman and CEO.
Guidance: Glaukos expects 2024 net sales of $377 million to $379 million, compared to a consensus of $373.758 million and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b40080668/glaukos-announces-second-quarter-2024-financial-results" rel="noreferrer noopener">prior guidance of</a> $370 million-$376 million.
William Blair wrote, &#8220;We believe part of the stock move down following results — indicated down 9% in the after-hours market despite another strong quarter, though the best performance to date in our coverage up 65% — was a result of the increase of only $3 million on the high end.&#8221;
The analyst highlighted the company anticipates peak headwinds from the Medicaid Drug Rebate Program (MDRP) in the fourth quarter, along with increasing competition in its international glaucoma segment, aligning with prior management guidance.
Additionally, William Blair projects that these competitive pressures could ease with upcoming key product approvals, set to expand the company&#8217;s international pipeline in the coming quarters.
GKOS Price Action: Glaukos Corp. stock is down 1.16% at $129.83 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41747460/dupont-q3-earnings-eps-beats-while-sales-lag-revises-annual-outlook-more" target="_blank" rel="noreferrer noopener">DuPont Q3 Earnings: EPS Beats While Sales Lag, Revises Annual Outlook &amp; More</a></li>
</ul>
Photo: Pixabay

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

GKOS

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

JP Morgan analyst Allen Gong maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $130 to $145.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $145

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $135 to $145.

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $145

WIIM

Glaukos shares are trading lower. The company reported Q3 financial results.

Glaukos Sees 2024 Net Sales $377M-$379M

Earnings Beats

Glaukos Q3 2024 Adj. EPS $(0.28) Beats $(0.48) Estimate, Sales $96.700M Beat $91.494M Estimate

Glaukos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) short percent of float has fallen 24.51% since its last report. The company recently reported that it has 2.38 million shares sold short, which is 6.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Glaukos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730298620_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Glaukos has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Glaukos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Glaukos's peer group average for short interest as a percentage of float is 4.15%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Glaukos?

Glaukos Says Phase 3 Confirmatory Trial Of Epioxa Met Pre-Specified Primary Efficacy Endpoint And Showed Tolerability, Favorable Safety Profile Through 12 Months

Across the recent three months, 7 analysts have shared their insights on Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $141.86, a high estimate of $152.00, and a low estimate of $135.00. Observing a 9.37% increase, the current average has risen from the previous average price target of $129.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1728918028_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Glaukos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$131.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Glaukos's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Glaukos's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>About Glaukos</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Breaking Down Glaukos's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Glaukos displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 19.02%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Glaukos's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -52.82%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glaukos's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -9.06%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Glaukos's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.46%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Glaukos's debt-to-equity ratio is below the industry average at 0.24, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 7 Analyst Recommendations For Glaukos

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $145 to $152.

Truist Securities Maintains Buy on Glaukos, Raises Price Target to $152

Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The strength in the iStent product line and solid execution across its global glaucoma and Corneal Health franchises augur well.
The sustained recovery trends across segments and solid business prospects in spite of the pandemic-induced uncertainties raise optimism. Recent strategic alliances instill confidence in the stock.
The company is also engaged in boosting its portfolio through the development of new products. It currently has seven clinical-stage trials and another three preclinical development programs underway. A number of these pipeline programs are in active pivotal clinical trials, including iLution Travoprost, iDose ROCK and iDose TREX.
The company&#39;s shares have risen 58.2% year to date compared with the industry&#39;s 8.4% growth. The rally was primarily driven by top-line growth in the past few quarters. The S&amp;P 500 Index was up 14.4% in the same time frame.
However, stiff competition in the medical device industry and vendor uncertainty are other headwinds. Meanwhile, a stringent regulatory approval process for the iDose platform and products is a woe.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b6/77271.jpg?v=801173257" />
Image Source: Zacks Investment Research
<h2>GKOS&#39; Products Driving Strong Business Performance</h2>
During the second quarter, GKOS&#39; glaucoma franchise witnessed growth in revenues, driven by its iStent portfolio, coupled with growing contributions from iDose TR. The company commenced the initial phases of the controlled launch plan for iDose TR during the reported quarter.
Per the second-quarter 2024 earnings call, iStent continued to demonstrate robust demand with positive surgeon feedback. This primarily highlights its three-stent solution favorable safety profile and streamlined injector system. The company&#39;s continued advancement in key market access initiatives for iStent infinite looks promising.
Continued strong demand across international glaucoma and Corneal Health franchises should be the key top-line drivers in 2024. Moreover, the commercial launch of iStent Infinite in 2023 is boosting the U.S. glaucoma franchise, which should drive growth in the upcoming few quarters.
The unique permanent J-code for iDose TR became effective from July 1. This is likely to increase patient access, driving sales growth in the upcoming quarters. The franchise also benefited from rapid international expansion.
<h2>Clinical Progress Drives GKOS&#39; Prospects</h2>
Clinical trials are the primary means to evaluate the efficacy and safety of new medical technologies.
Glaukos is currently developing several pipeline products, namely iDose TREX, iDose ROCK and iLution Travoprost. These next-generation extended-release candidates are in different stages of clinical development. Successful development, followed by a potential launch of these products, should boost Glaukos&#39; glaucoma portfolio.
The iDose TR candidate received the FDA approval in December 2023. The candidate, a targeted injectable implant, demonstrated tolerability and a favorable safety profile through 12 months in a late-stage clinical study.
Glaukos is also evaluating iLink system using Epioxa therapy for the treatment of keratoconus without the removal of the epithelium in a phase III study. The company has already completed one phase III study in 2021 on iLink. A potential new drug application is expected to be filed by the end of 2024.
The company commenced three new clinical trials during the fourth quarter of 2023 &mdash; a PMA clinical trial for iStent infinite in mild-to-moderate glaucoma patients; a Phase 2a study for iLution Travoprost; and a first-in-human clinical development program for GLK-401, an intravitreal multi-kinaseinhibitor retinal program for wet AMD patients. The company plans to start a phase 3 study for iDose TREX later in 2024 and complete enrollment in Phase 2 trials for its iLink third-generation therapy.
<h2>International Market Holds Potential for GKOS</h2>
Apart from the U.S. market, Glaukos is also focusing on expanding on a global scale. The company has been developing a sales base and increasing its marketing and market access efforts. It currently sells its products primarily through direct sales subsidiaries in 17 countries and independent distributors in certain nations.
GKOS&#39; continued efforts to scale its international infrastructure and execute the plans to position MIGS as a standard of care in each region and every major market in the world will likely boost glaucoma revenues going forward. The company&#39;s efforts have been positively impacting its international growth.
In the fourth quarter of 2023, the company&#39;s Glaucoma sales were up more than 25%. Corneal Health sales improved 19% in international markets. Continued broad-based growing demand in many key international markets for combined cataract and glaucoma procedures is likely to continue in the upcoming few quarters.
<h2>Factors Hurting the Stock</h2>
Glaukos&#39; competitors include medical companies, academic and research institutions, and others that develop new drugs, therapies, medical devices or surgical procedures to treat glaucoma. Thus, intense competition continues to weigh on the company&#39;s overall performance.
GKOS currently relies on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models and other pipeline products. If any one or more of these suppliers cease to provide the company with sufficient quantities of components or drugs in a timely manner or on acceptable terms, it would have to seek alternate sources of supply.
Additionally, some of the vendors continue to experience challenges pertaining to supply of raw materials and labor shortages. As a result of these supply chain challenges and current inflationary pressures, Glaukos has experienced higher costs for certain components and raw materials. These setbacks are likely to remain for the rest of 2024, albeit at a slower pace.&nbsp;
<div class="chart_embed">
<h3>Glaukos Corporation Price</h3>
<img alt="Glaukos Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/0f/1726048478.png" style="height:251px; width:575px" title="" />
Glaukos Corporation price | Glaukos Corporation Quote
</div>
<h2>GKOS&#39; Zacks Rank &amp; Stocks to Consider</h2>
Glauos currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Quest Diagnostics Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and Boston Scientific Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%.
DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 24.2%. Its shares have risen 56.9% compared with the industry&#39;s 27.5% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.
Quest Diagnostics&#39; shares have risen 21.6% compared with the industry&#39;s 27.5% growth in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 50.8% compared with the industry&#39;s 17.2% growth in the past year.
<a href="https://www.zacks.com/stock/news/2334519/glaukos-stocks-rides-on-strong-product-demand-amid-competition?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2334519">To read this article on Zacks.com click here.</a>

Biotech

Large Cap

Mid Cap

Markets

Glaukos Stocks Rides on Strong Product Demand Amid Competition

Stifel analyst Thomas Stephan maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $130 to $145.

Stifel Maintains Buy on Glaukos, Raises Price Target to $145

In the latest quarter, 11 analysts provided ratings for Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Glaukos, revealing an average target of $133.64, a high estimate of $145.00, and a low estimate of $120.00. This current average has increased by 11.37% from the previous average price target of $120.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1724868076_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Glaukos among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$141.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$131.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Glaukos's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Glaukos's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>Get to Know Glaukos Better</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Financial Milestones: Glaukos's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Glaukos displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 19.02%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -52.82%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -9.06%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.46%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.24, Glaukos adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 11 Analyst Ratings For Glaukos

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $131 to $139.

BTIG Maintains Buy on Glaukos, Raises Price Target to $139

Across the recent three months, 12 analysts have shared their insights on Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $132.17, a high estimate of $145.00, and a low estimate of $120.00. This upward trend is apparent, with the current average reflecting a 13.86% increase from the previous average price target of $116.08.
<img src="https://www.benzinga.com/files/images/story/2024/1722539236_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Glaukos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$141.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$131.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Sarcone</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Glaukos's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Glaukos's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>All You Need to Know About Glaukos</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Glaukos: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Glaukos's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 15.86%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Glaukos's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -47.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glaukos's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.95%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.36%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Glaukos's debt-to-equity ratio surpasses industry norms, standing at 0.85. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

Glaukos Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) reported second-quarter 2024 adjusted loss of 52 cents per share, in line with the Zacks Consensus Estimate. The figure was narrower than the year-ago quarter&#39;s adjusted loss of 55 cents per share.
The GAAP loss per share was $1.06 compared with the prior-year quarter&#39;s reported loss of 68 cents.
<h3>Revenue Details</h3>
Glaukos registered revenues of $95.7 million in the second quarter, up 19% year over year on a reported basis and 20% at constant currency (cc). The figure also surpassed the Zacks Consensus Estimate by 8.2%.
<h3>Quarter in Detail</h3>
The company recorded net sales of $75.9 million and $19.8 million for Glaucoma and Corneal Health, respectively, up 23% and 7% year over year.
<h3>Margin Trend</h3>
Gross profit increased 21.3% to $73.1 million. The adjusted gross margin was flat year over year at 82%.
Selling, general and administrative expenses rose 25% to $66.2 million. Research and development expenses totaled $34.4 million, up 4% year over year. Total operating expenses were $104.4 million, up 17.6% from that recorded in the prior-year period.
The operating loss amounted to $30 million compared with $32.9 million in the year-ago period. The adjusted operating loss was $23.7 million, wider than the year-ago quarter&#39;s reported loss of $22.8 million.
<h3>Financial Update</h3>
Glaukos exited the second quarter of 2024 with cash and cash equivalents and short-term investments of $266.4 million compared with $278.7 million at the end of the last reported quarter.
<h3>2024 Guidance</h3>
The company revised its guidance for 2024 revenues. It now expects net sales to be in the range of $370-$376 million compared with the previous guidance of $357-$365 million. The Zacks Consensus Estimate for the same is pegged at $362.8 million.
<div class="chart_embed">
<h3>Glaukos Corporation Price, Consensus and EPS Surprise</h3>
<img alt="Glaukos Corporation Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/f3/1722501633.png" style="height:265px; width:584px" title="" />
Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation Quote
</div>
<h3>Our Take</h3>
Glaukos&#39; second-quarter 2024 earnings met the Zacks Consensus Estimate, while revenues beat the same. Management remains excited regarding the company&#39;s continued top-line growth in the reported quarter.
During the second quarter, GKOS&#39; glaucoma franchise witnessed growth in revenues, driven by its iStent portfolio, coupled with growing contributions from iDose TR. The company commenced the initial phases of the controlled launch plan for iDose TR during the reported quarter. The unique permanent J-code for iDose TR became effective from Jul 1. This is likely to increase patient access, driving sales growth in the upcoming quarters. The franchise also benefited from rapid international expansion.
GKOS continues to invest in its product pipeline. It targets NDA submission for its corneal cross-linking therapy, Epioxa, by the end of 2024, which is currently progressing toward the second Phase 3 pivotal trial completion. The company remains on track to start a pivotal study on its next-generation iDose therapy, iDose TREX, by the end of 2024.
However, GKOS&#39; operating loss in the reported quarter amid rising costs and expenses raised our apprehension. Its operation in a stiff, competitive market is also worrisome.
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Cencora currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are&nbsp;Boston Scientific Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>),&nbsp;Hologic (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) and&nbsp;Universal Health Services.
Boston Scientific reported second-quarter 2024 adjusted EPS of 62 cents, which beat the Zacks Consensus Estimate by 6.9%. Revenues of $4.12 billion surpassed the Zacks Consensus Estimate by 2.5%. It currently carries a Zacks Rank of 2 (Buy).
Boston Scientific has a long-term growth rate of 12.5%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
Hologic, carrying a Zacks Rank of 2 at present, has a long-term growth rate of 7.4%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.50%.
Hologic reported second-quarter 2024 adjusted EPS of $1.06, which beat the Zacks Consensus Estimate by 3.9%. Revenues of $1 billion surpassed the Zacks Consensus Estimate by 1.1%.
Universal Health Services reported second-quarter 2024 adjusted EPS of $4.31, which beat the Zacks Consensus Estimate by 27.9%. Revenues of $3.9 billion surpassed the Zacks Consensus Estimate by 1.5%.
Universal Health Services has a long-term growth rate of 18%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
<a href="https://www.zacks.com/stock/news/2313906/glaukos-gkos-q2-earnings-in-line-glaucoma-drives-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-2313906">To read this article on Zacks.com click here.</a>

HOLX

Glaukos Q2 Earnings In Line, Glaucoma Drives Sales

Piper Sandler analyst Matt O'Brien maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $110 to $140.

Piper Sandler Maintains Overweight on Glaukos, Raises Price Target to $140

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $120 to $135.

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $135

Truist Securities analyst Richard Newitter reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $141 to $145.

Reiteration

Truist Securities Reiterates Buy on Glaukos, Raises Price Target to $145

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley raised the price target for Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) from $18 to $30. Morgan Stanley analyst Elizabeth Porter downgraded the stock from Overweight to Equal-Weight. Zeta Global shares rose 2.1% to close at $21.42 on Wednesday. <a href="https://www.benzinga.com/quote/ZETA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted the price target for Glaukos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NASDAQ">GKOS</a>) from $131 to $137. Needham analyst David Saxon maintained a Buy rating. Glaukos shares fell 0.6% to close at $117.17 on Wednesday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased Day One Biopharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) price target from $11 to $24. B of A Securities analyst Alec Stranahan upgraded the stock from Underperform to Buy. Day One Biopharmaceuticals shares fell 5.8% to close at $14.31 on Wednesday. <a href="https://www.benzinga.com/quote/DAWN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) from $562 to $643. Rosenblatt analyst Barton Crockett maintained a Buy rating. Meta shares gained 2.5% to close at $474.83 on Thursday.<a href="https://www.benzinga.com/quote/META/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Rosenblatt raised QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) price target from $240 to $250. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. QUALCOMM shares rose 8.4% to close at $180.95 on Wednesday. <a href="https://www.benzinga.com/quote/QCOM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $213 to $226. B of A Securities analyst Joshua Shanker maintained a Buy rating. Allstate shares fell 1.4% to close at $171.12 on Wednesday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) from $175 to $220. Morgan Stanley analyst Andrew Percoco upgraded the stock from Equal-Weight to Overweight. GE Vernova shares gained 9.6% to close at $178.24 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>Baird boosted Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) price target from $142 to $163. Baird analyst Michael Halloran maintained a Neutral rating. Generac shares rose 0.1% to close at $155.68 on Wednesday. <a href="https://www.benzinga.com/quote/GNRC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital increased Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) price target from $68 to $84. Loop Capital analyst Yun Kim upgraded the stock from Hold to Buy. Pegasystems shares fell 1.4% to close at $69.72 on Wednesday. <a href="https://www.benzinga.com/quote/PEGA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners boosted Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) price target from $325 to $375. Leerink Partners analyst Puneet Souda upgraded the stock from Market Perform to Outperform. Waters shares gained 2.6% to close at $336.28 on Wednesday. <a href="https://www.benzinga.com/quote/WAT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40092288/nasdaq-settles-higher-as-nvidia-records-best-session-since-february-fear-greed-index-now-in-neutral"> Nasdaq Settles Higher As Nvidia Records Best Session Since February: Fear &amp; Greed Index Now In &#8216;Neutral&#8217; Zone As Investor Sentiment Improves</a></li>
</ul>

Pre-Market Outlook

DAWN

GNRC

PEGA

QCOM

ZETA

Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Glaukos Corp. ( ($GKOS) ) has released its Q3 earnings. Here is a breakdown of the information Glaukos Corp. presented to its investors. Glaukos Co...

Glaukos Corp. Reports Record Third-Quarter Sales Growth

In a report released today, David Saxon from Needham reiterated a Buy rating on Glaukos (GKOS – Research Report), with a price target of $149.00. D...

Glaukos' Strong Q3 2024 Performance and iDose's Growth Propel Buy Rating

Analyst Ryan Zimmerman from BTIG reiterated a Buy rating on Glaukos (GKOS – Research Report) and increased the price target to $140.00 from $139.00...

Strong Financial Performance and Promising Growth Prospects Drive Buy Rating for Glaukos

Glaukos (GKOS) Receives a Buy from Piper Sandler

BTIG raised the firm's price target on Glaukos (GKOS) to $140 from $139 and keeps a Buy rating on the shares. The company's Q3 results topped conse...

Glaukos price target raised to $140 from $139 at BTIG

Mizuho Securities analyst Anthony Petrone has maintained their neutral stance on GKOS stock, giving a Hold rating yesterday. Anthony Petrone has gi...

Uncertain Growth and Reimbursement Challenges Keep Glaukos's iDose at Hold Rating

Lord Abbett Developing Growth Fund Q3 2024 Commentary

The latest announcement is out from Glaukos ( ($GKOS) ). Glaukos Corporation's innovative iDose TR therapy is set to revolutionize glaucoma treatme...

Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval

In a report released today, Thomas Stephan from Stifel Nicolaus maintained a Buy rating on Glaukos (GKOS – Research Report), with a price target of...

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

ADMA

CAVA

CYBR

FROG

LOAR

PIPR

RXST

TMDX

VRNS

Press Releases

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Glaukos Announces Second Quarter 2024 Financial Results

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Comments

Glaukos

空売り

Glaukos (NYSE:GKOS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル